3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
BRAF V600E Mutation
1
Interventions
Cytarabine
21
Cyclophosphamide
21
fludarabine
18
Whole-Body Irradiation
18
venetoclax
15
fludarabine phosphate
15
Specimen Handling
15
Methotrexate
15
Mycophenolic Acid
13
Vincristine
9
Biopsy
9
merphos
8
Granulocyte Colony-Stimulating Factor
8
Filgrastim
8
Dexamethasone
8
calaspargase pegol
7
blinatumomab
7
Stem Cell Transplantation
7
Peripheral Blood Stem Cell Transplantation
7
Hydrocortisone
7
Busulfan
7
Azacitidine
7
revumenib
6
Tacrolimus
6
Melphalan
6
Idarubicin
6
Daunorubicin
6
Asparaginase
6
X-Rays
5
Thiotepa
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Biphenotypic, Acute
×
Cobicistat
×
1 year
×
Clear all
NCT04065399
2026-03-18
AUGMENT-101
Syndax Pharmaceuticals
Phase 1/2
Recruiting
447 enrolled
2 FDA